Results 81 to 90 of about 1,458 (171)

Advancing Therapeutic Drug Monitoring for Oral Targeted Anticancer Drugs: From Hospital‐Based Towards Home‐Sampling

Biomedical Chromatography, Volume 39, Issue 5, May 2025.
ABSTRACT Home‐sampling for therapeutic drug monitoring (TDM) for oral targeted anticancer drugs offers a promising alternative to traditional hospital‐based sampling methods, though it presents challenges. This review aims to summarize the state‐of‐the‐art of home‐sampling methods for TDM and evaluates the analytical and clinical validation challenges.
Marinda Meertens, Hilde Rosing, Neeltje Steeghs, Jos H. Beijnen, Alwin D. R. Huitema   +4 more
wiley   +1 more source

Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review

Diagnostics, 2019
Poly (ADP-ribose) polymerase (PARP) inhibitors are the first clinically approved drugs designed to exploit synthetic lethality, and were first introduced as a cancer-targeting strategy in 2005. They have led to a major change in the treatment of advanced
Stergios Boussios, Peeter Karihtala, Michele Moschetta, Afroditi Karathanasi, Agne Sadauskaite, Elie Rassy, Nicholas Pavlidis   +6 more
doaj   +1 more source

WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations

Cancers
Inhibition of WEE1, a key regulator of the G2/M checkpoint of the cell cycle, induces apoptosis by initiating mitosis without repairing DNA damage. However, the effects of WEE1 inhibitors on the tumor immune microenvironment in colorectal cancer (CRC) remain unclear.
Misa Ariyoshi, Ryo Yuge, Yuki Kitadai, Daisuke Shimizu, Ryo Miyamoto, Ken Yamashita, Yuichi Hiyama, Hidehiko Takigawa, Yuji Urabe, Shiro Oka   +9 more
openaire   +2 more sources

Supplementary Figure S4 from Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck

, 2019
Supplementary Figure S4 related to Figure 5D-F. (A) Individual tumor volume changes in Detroit 562-xenografted mice treated with vehicle, adavosertib (30 mg/kg, daily, p.o.), alisertib (30 mg/kg, daily, p.o.), or the combinations of alisertib with ...
Jeffrey P. Townsend (14963915), Dong-hua Yang (15012759), Ja Seok Koo (14888484), Kyung Jin Eoh (8568471), Wendell G. Yarbrough (232305), Janaki Parameswaran (15012753), Erica A. Golemis (14949004), Natalia Issaeva (839371), Stephen G. Gaffney (15012762), Ilya G. Serebriiskii (14893961), Barbara Burtness (550227), Jong Woo Lee (360063), Fang Zhu (185566), Ranee Mehra (5707862), Teresa Sandoval-Schaefer (15012756), Roshan Sharma (5904719), Elizabeth B. Perry (14920176)   +16 more
core   +1 more source

Preparation and metabolism of tyrosine kinase inhibitors in nanotransporters [PDF]

, 2021
Cancer is currently one of the major diseases of civilization, so it is no wonder that in recent decades its research has been a priority for many laboratories.
Urbanová, Tereza
core  

Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review

Taiwanese Journal of Obstetrics & Gynecology
Platinum-resistant ovarian cancer (PROC) refers to disease progression within 6 months after the completion of platinum-based chemotherapy. Historically, treatment options for PROC were limited with a poor prognosis and non-platinum single agent plus ...
Hao Lin, Chen-Hsuan Wu, Hung-Chun Fu, Yu-Che Ou   +3 more
doaj   +1 more source

Efficacy and Safety of Adavosertib in Platinum-Resistant and RecurrentOvarian Cancer: A Systematic Review and A Meta-Analysis

Journal of Gynecology Research Reviews & Reports
Introduction: Ovarian cancer is a leading cause of mortality among gynaecological malignancies. According to estimates from the American Cancer Society for 2024, approximately 19,680 women in the United States will be newly diagnosed with ovarian cancer, and about 12,740 women will succumb to the disease.
Pavan Kumar Reddy Kalluru, Sai Sudha Valisekka, Deekshitha Kuchi, Abijay Reddy Bhoomireddy, Apoorva Cherukuri, Gaurav Venkat Cuddapah, Sai Goutham Reddy Yartha, Sowmya Manjari Siddenthi, Niravkumar Brahmbhatt, Pawan Kumar Thada, Samhitha Gundakaram, Haritha Reddy Kalluru   +11 more
openaire   +1 more source

Targeting WEE1 Kinase in Gynecological Malignancies

Drug Design, Development and Therapy
Wenhao Zhang,1,2 Qingli Li,1,2,* Rutie Yin1,2,* 1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu, People’s Republic of China; 2Key Laboratory of Birth Defects and Related Diseases of ...
Zhang W, Li Q, Yin R
doaj  

WEE1 as a checkpoint regulator and therapeutic vulnerability: From biology to clinical development

SAGE Open Medicine
WEE1 is a critical cell-cycle checkpoint kinase that inhibits cyclin-dependent kinase activity via phosphorylation, coordinating DNA replication, repair, and mitotic entry.
Huiting Jia, Menghua Dong
doaj   +1 more source

Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma

Haematologica
Diffuse large B-cell lymphoma (DLBCL) is the most common malignancy that develops in patients with ataxia-telangiectasia, a cancer-predisposing inherited syndrome characterized by inactivating germline ATM mutations.
Nicholas Davies, Tegan Francis, Ceri Oldreive, Maria Azam, Jordan Wilson, Philip J. Byrd, Megan Burley, Archana Sharma-Oates, Peter Keane, Sael Alatawi, Martin R. Higgs, Zbigniew Rudzki, Maha Ibrahim, Tracey Perry, Angelo Agathaggelou, Anne-Marie Hewitt, Edward Smith, Constanze Bonifer, Mark O’Connor, Josep V. Forment, Paul G. Murray, Eanna Fennell, Gemma Kelly, Catherine Chang, Grant S. Stewart, Tatjana Stankovic, Marwan Kwok, Alexander Malcolm Taylor   +27 more
doaj   +1 more source